Q1 Earnings Forecast for SLDB Issued By Leerink Partnrs

Key Points

• Leerink Partners forecasts Solid Biosciences' Q1 2026 EPS at ($0.46) and expects full-year earnings of ($2.84) per share.
• JPMorgan Chase & Co. and Piper Sandler have recently adjusted their price targets on Solid Biosciences, currently set at $13.00 and $17.00 respectively, maintaining an "overweight" rating.
• Solid Biosciences shares experienced a trading decline of 1.1%, with the stock currently priced at $6.11, amid fluctuating trading volumes.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of Solid Biosciences in a report released on Wednesday, August 13th. Leerink Partnrs analyst J. Schwartz expects that the company will earn ($0.46) per share for the quarter. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Solid Biosciences' Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.50) EPS and Q4 2026 earnings at ($0.48) EPS.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.09.

Other analysts have also recently issued reports about the company. Chardan Capital reiterated a "buy" rating and set a $15.00 price target on shares of Solid Biosciences in a research report on Thursday, August 14th. Cantor Fitzgerald set a $16.00 price target on Solid Biosciences and gave the stock an "overweight" rating in a research report on Monday, July 21st. Piper Sandler dropped their target price on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating for the company in a report on Friday, May 16th. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Solid Biosciences in a report on Tuesday, June 17th. Finally, Barclays dropped their target price on Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating for the company in a report on Friday, May 16th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $15.00.

Solid Biosciences Stock Performance

Shares of SLDB traded down $0.08 during trading hours on Friday, hitting $5.96. 53,642 shares of the stock were exchanged, compared to its average volume of 1,923,945. Solid Biosciences has a 12-month low of $2.41 and a 12-month high of $10.37. The company has a market cap of $463.71 million, a price-to-earnings ratio of -2.13 and a beta of 2.44. The stock's 50-day moving average price is $5.65 and its two-hundred day moving average price is $4.47.

Hedge Funds Weigh In On Solid Biosciences

Large investors have recently modified their holdings of the business. Legal & General Group Plc lifted its stake in shares of Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company's stock valued at $29,000 after purchasing an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock valued at $33,000 after purchasing an additional 4,534 shares during the last quarter. CWM LLC lifted its stake in shares of Solid Biosciences by 15,188.5% in the 1st quarter. CWM LLC now owns 7,950 shares of the company's stock valued at $29,000 after purchasing an additional 7,898 shares during the last quarter. Corton Capital Inc. acquired a new position in shares of Solid Biosciences in the 4th quarter valued at $41,000. Finally, Pallas Capital Advisors LLC acquired a new position in shares of Solid Biosciences in the 2nd quarter valued at $54,000. Institutional investors and hedge funds own 81.46% of the company's stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.